BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually
Speed, Quality, Productivity Drive Research Efforts
Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.
After serial failures with tau antibodies for Alzheimer’s, BMS’ expanded deal with Prothena signals its growing confidence in PRX005, a new molecule targeting a different region on the toxic protein.
Giovanni Caforio will step down as CEO of Bristol Myer Squibb effective 1 November, with chief commercialization officer Boerner primed to succeed him.